Treatment of bleomycin-induced pulmonary fibrosis by inhaled tacrolimus-loaded chitosan-coated poly(lactic-co-glycolic acid) nanoparticles

Biomedicine and Pharmacotherapy

Volumn 78, Issue , 2016, Pages 226-233

  Lee, Changkyu ^a   Seo, Jisoo ^a   Hwang, Ha Shin ^a   Thao, Le Quang ^a   Lee, Seunghyun ^a   Lee, Eun Seong ^b   Lee, Eun Hee ^c   Choi, Han Gon ^d   Youn, Yu Seok ^a  

^a Sungkyunkwan University   (South Korea)

^b The Catholic University of Korea   (South Korea)

^c Korea University   (South Korea)

^d Hanyang University   (South Korea)

Author keywords

Chitosan; Inhalation; PLGA nanoparticle; Pulmonary fibrosis; Tacrolimus

Indexed keywords

CHITOSAN; NANOPARTICLE; POLYGLACTIN; TACROLIMUS; AEROSOL; BLEOMYCIN; COLLAGEN; HYDROXYPROLINE; LACTIC ACID; POLYGLYCOLIC ACID; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLEOMYCIN-INDUCED PULMONARY FIBROSIS; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DIFFUSION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; LUNG FIBROSIS; MALE; MOUSE; NANOEMULSION; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; STAINING; SUSTAINED DRUG RELEASE; ZETA POTENTIAL; AEROSOL; ANIMAL; C57BL MOUSE; CHEMICALLY INDUCED; CHEMISTRY; DRUG EFFECTS; INHALATIONAL DRUG ADMINISTRATION; LUNG; METABOLISM; PATHOLOGY; PULMONARY FIBROSIS; STATIC ELECTRICITY; SURFACE PROPERTY; THREE DIMENSIONAL IMAGING; ULTRASTRUCTURE; X RAY DIFFRACTION;

ADMINISTRATION, INHALATION; AEROSOLS; ANIMALS; BLEOMYCIN; CHITOSAN; COLLAGEN; HYDROXYPROLINE; IMAGING, THREE-DIMENSIONAL; LACTIC ACID; LUNG; MALE; MICE, INBRED C57BL; NANOPARTICLES; PARTICLE SIZE; POLYGLYCOLIC ACID; PULMONARY FIBROSIS; STATIC ELECTRICITY; SURFACE PROPERTIES; TACROLIMUS; X-RAY DIFFRACTION;

EID: 84958622047     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2016.01.027     Document Type: Article

References (34)

1. Qu Y., Zhang L., Kang Z., Jiang W., Lv C. Ponatinib ameliorates pulmonary fibrosis by suppressing TGF-β1/Smad3 pathway. Pulm. Pharmacol. Ther. 2015, 34:1-7.
2. Noble P.W., Homer R.J. Back to the future. Am. J. Respir. Cell Mol. Biol. 2005, 33:113-120.
3. Horita N., Akahane M., Okada Y., Kobayashi Y., Arai T., Amano I., et al. Tacrolimus and steroid treatment for acute exacerbation of idiopathic pulmonary fibrosis. Intern. Med. 2011, 50:189-195.
4. Patel P., Patel H., Mehta T., Panchal S. Formulation strategies for drug delivery of tacrolimus: an overview. Int. J. Pharm. Invest. 2012, 2:169-175.
5. Choi S.H., Byeon H.J., Choi J.S., Thao L., Kim I., Lee E.S., et al. Inhalable self-assembled albumin nanoparticles for treating drug-resistant lung cancer. J. Control. Release 2015, 197:199-207.
6. Letko E., Bhol K., Pinar V., Foster C.S., Ahmed A.R. Tacrolimus (FK 506). Ann. Allergy Asthma Immunol. 1999, 83:179-190.
7. Tamura S., Ohike A., Ibuki R., Amidon G.L., Yamashita S. Tacrolimus is a class II low-solubility high-permeability drug: the effect of P-glycoprotein efflux on regional permeability of tacrolimus in rats. J. Pharm. Sci. 2002, 91:719-729.
8. Shin S.B., Cho H.Y., Kim D.D., Choi H.G., Lee Y.B. Preparation and evaluation of tacrolimus-loaded nanoparticles for lymphatic delivery. Eur. J. Pharm. Biopharm. 2010, 74:164-171.
9. Surassmo S., Saengkrit N., Ruktanonchai U.R., Suktham K., Woramongkolchai N., Wutikhun T., et al. Surface modification of PLGA nanoparticles by carbopol to enhance mucoadhesion and cell internalization. Colloids Surf. B: Biointerfaces 2015, 130:229-236.
10. Surapaneni S.K., Das N.G. Designing paclitaxel drug delivery systems aimed at improved patient outcomes: current status and challenges. ISRN Pharmacol. 2012, 2012:1-15.
11. Yang R., Shim W.S., Cui F.D., Cheng G., Han X., Jin Q.R., et al. Enhanced electrostatic interaction between chitosan-modified PLGA nanoparticle and tumor. Int. J. Pharm. 2009, 371:142-147.
12. Lauweryns J.M., Baert J.H. Alveolar clearance and the role of the pulmonary lymphatics. Am. Rev. Respir. Dis. 1977, 115:625-683.
13. Makhlof A., Werle M., Tozuka Y., Takeuchi H. Nanoparticles of glycol chitosan and its thiolated derivative significantly improved the pulmonary delivery of calcitonin. Int. J. Pharm. 2010, 397:92-95.
14. Lee C., Choi J.S., Kim I., Oh K.T., Lee E.S., Park E.S., et al. Long-acting inhalable chitosan-coated poly(lactic-co-glycolic acid) nanoparticles containing hydrophobically modified exendin-for treating type 2 diabetes. Int. J. Nanomed. 2013, 8:2975-2983.
15. Lamprecht A., Yamamoto H., Takeuchi H., Kawashima Y. A pH-sensitive microsphere system for the colon delivery of tacrolimus containing nanoparticles. J. Control. Release 2005, 104:337-346.
16. Nagano J., Iyonaga K., Kawamura K., Yamashita A., Ichiyasu H., Okamoto T., et al. Use of tacrolimus a potent antifibrotic agent, in bleomycin-induced lung fibrosis. Eur. Respir. J. 2006, 27:460-469.
17. Shivshankar P., Payan H., Calhoun C., Levine S., Williams R.O., Jagirdar J., et al. Inhaled tacrolimus modulates pulmonary fibrosis without promoting inflammation in bleomycin-injured mice. J. Drug Deliv. Sci. Technol. 2014, 24:469-477.
18. Tanaka R., Watanabe H., Kodama A., Chuang V.T., Ishima Y., Hamasaki K., et al. Long-acting human serum albumin-thioredoxin fusion protein suppresses bleomycin-induced pulmonary fibrosis progression. J. Pharmacol. Exp. Ther. 2013, 345:271-283.
19. Giri S.N., Hyde D.M., Hollinger M.A. Effect of antibody to transforming growth factor beta on bleomycin induced accumulation of lung collagen in mice. Thorax 1993, 48:959-966.
20. Kim I., Byeon H.J., Kim T.H., Lee E.S., Oh K.T., Shin B.S., et al. Doxorubicin-loaded highly porous large PLGA microparticles as a sustained-release inhalation system for the treatment of metastatic lung cancer. Biomaterials 2012, 33:5574-5583.
21. Liu W., Wan J., Han J.Z., Li C., Feng D.D., Yue S.J., et al. Antiflammin-attenuates bleomycin-induced pulmonary fibrosis in mice. Respir. Res. 2013, 14:101.
22. Moore B.B., Hogaboam C.M. Murine models of pulmonary fibrosis. Am. J. Physiol. Lung Cell. Mol. Physiol. 2008, 294:L152-160.
23. Bartram U., Speer C.P. The role of transforming growth factor beta in lung development and disease. Chest 2004, 125:754-765.
24. Kim I., Byeon H.J., Kim T.H., Lee E.S., Oh K.T., Shin B.S., et al. Doxorubicin-loaded porous PLGA microparticles with surface attached TRAIL for the inhalation treatment of metastatic lung cancer. Biomaterials 2013, 34:6444-6453.
25. Mittal G., Sahana D.K., Bhardwaj V., Ravi Kumar M.N. Estradiol loaded PLGA nanoparticles for oral administration: effect of polymer molecular weight and copolymer composition on release behavior in vitro and in vivo. J. Control. Release 2007, 119:77-85.
26. Barahuie F., Hussein M.Z., Hussein-Al-Ali S.H., Arulselvan P., Fakurazi S., Zainal Z. Preparation and controlled-release studies of a protocatechuic acid-magnesium/aluminumlayered double hydroxide nanocomposite. Int. J. Nanomed. 2013, 8:1975-1987.
27. Yamamoto H., Kuno Y., Sugimoto S., Takeuchi H., Kawashima Y. Surface-modified PLGA nanosphere with chitosan improved pulmonary delivery of calcitonin by mucoadhesion and opening of the intercellular tight junctions. J. Control. Release 2005, 102:373-381.
28. Guo M., Rong W.T., Hou J., Wang D.F., Lu Y., Wang Y., et al. Mechanisms of chitosan-coated poly(lactic-co-glycolic acid) nanoparticles for improving oral absorption of 7-ethyl-10-hydroxycamptothecin. Nanotechnology 2013, 24:245101.
29. Lu Z., Yeh T., Tsai M., Au J.L., Wientjes M.G. Paclitaxel-loaded gelatin nanoparticles for intravesical bladder cancer therapy. Clin. Cancer Res. 2004, 10:7677-7684.
30. Moeller A., Ask K., Warburton D., Gauldie J., Kolb M. The bleomycin animal model: a useful tool to investigate treatment options for idiopathic pulmonary fibrosis?. Int. J. Biochem. Cell Biol. 2008, 40:362-382.
31. Koshika T., Hirayama Y., Ohkubo Y., Mutoh S., Ishizaka A. Tacrolimus (FK506) has protective actions against murine bleomycin-induced acute lung injuries. Eur. J. Pharmacol. 2005, 515:169-178.
32. Kim S.N., Lee J., Yang H.S., Cho J.W., Kwon S., Kim Y.B., et al. Dose-response effects of bleomycin on inflammation and pulmonary fibrosis in mice. Toxicol. Res. 2010, 26:217-222.
33. Crystal R.G. Lung collagen: definition, diversity and development. Fed. Proc. 1974, 33:2248-2255.
34. Wuyts W.A., Willems S., Vos R., Vanaudenaerde B.M., De Vleeschauwer S.I., Rinaldi M., et al. Azithromycin reduces pulmonary fibrosis in a bleomycin mouse model. Exp. Lung Res. 2010, 36:602-614.